ErVimmune

ErVimmune develops breakthrough immunotherapies based on the identification of non-conventional tumor antigens shared across tumors and patients.

ErVimmune identifies & targets viral remnants (HERVs) in tumors, shared across patients, thanks to proprietary bioinformatic algorithms allowing an AI-powered selection to ensure potent & safe tumor targeting.

Our initial targeted indication is triple negative breast cancer (TNBC) with PoC demonstrating the ability of HERV-specific T-cells to recognize and eliminate TNBC cells, with strong backing from FDA/EMA and major publications.